Anti-cancer drug discovery flawed, researchers claim
A team from Vanderbilt University (Nashville, TN, USA) has concluded that the current primary means of testing compounds for anti-cancer activity in cells is flawed, findings that may have far-reaching effects in the field of drug discovery.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>